Literature DB >> 6175571

Brain endo-oligopeptidase B: a post-proline cleaving enzyme that inactivates angiotensin I and II.

L J Greene, A C Spadaro, A R Martins, W D Perussi De Jesus, A C Camargo.   

Abstract

Rabbit brain endo-oligopeptidase B inactivates angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) and angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) by hydrolysis of the Pro7-Phe8 peptide bond. The site of hydrolysis was determined in preparative and analytical experiments in which both products were recovered in a molar ratio of 1:1, and the sum of the products plus unhydrolyzed substrate accounted for the starting material. The enzyme has a Km of 6.3 x 10(-5) M for angiotensin II at pH 8.3 and is activated 30-fold with 4.8 mM dithiothreitol. BPP9a ( less than Gln-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro, SQ 20,881) inhibits the inactivation of angiotensin II with an I50 of 5 x 10(-5) M. BPP5a (less than Gln-Lys-Trp-Ala-Pro, SQ 20,475) is less active and D-3-mercapto-2-methylpropanoyl-L-proline (captopril, SQ 14,225) has essentially no activity. These endo-oligopeptidase B in angiotensin I and II metabolism remains to be established.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6175571     DOI: 10.1161/01.hyp.4.2.178

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

1.  Angiotensin-converting enzyme inhibition, but not AT(1) receptor blockade, in the solitary tract nucleus improves baroreflex sensitivity in anesthetized transgenic hypertensive (mRen2)27 rats.

Authors:  Katsunori Isa; Amy C Arnold; Brian M Westwood; Mark C Chappell; Debra I Diz
Journal:  Hypertens Res       Date:  2011-09-22       Impact factor: 3.872

2.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

3.  Renin and cardiovascular disease: Worn-out path, or new direction.

Authors:  Gaurav Alreja; Jacob Joseph
Journal:  World J Cardiol       Date:  2011-03-26

Review 4.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

5.  Nanoparticles targeting the infarcted heart.

Authors:  Tal Dvir; Michael Bauer; Avi Schroeder; Jonathan H Tsui; Daniel G Anderson; Robert Langer; Ronglih Liao; Daniel S Kohane
Journal:  Nano Lett       Date:  2011-09-14       Impact factor: 11.189

6.  Enzymatic inactivation of bradykinin by rat brain neuronal perikarya.

Authors:  E A DelBel; A P Padovan; G J Padovan; O Z Sellinger; A R Martins
Journal:  Cell Mol Neurobiol       Date:  1989-09       Impact factor: 5.046

7.  Endothelial metabolism of angiotensin II to angiotensin III, not angiotensin (1-7), augments the vasorelaxation response in adrenal cortical arteries.

Authors:  Phillip G Kopf; William B Campbell
Journal:  Endocrinology       Date:  2013-10-03       Impact factor: 4.736

8.  Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent.

Authors:  Peter Serfozo; Jan Wysocki; Gvantca Gulua; Arndt Schulze; Minghao Ye; Pan Liu; Jing Jin; Michael Bader; Timo Myöhänen; J Arturo García-Horsman; Daniel Batlle
Journal:  Hypertension       Date:  2019-12-02       Impact factor: 10.190

Review 9.  Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension.

Authors:  Scott S Billecke; Pamela A Marcovitz
Journal:  Vasc Health Risk Manag       Date:  2013-03-16

Review 10.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.